Lv3
370 积分 2023-09-29 加入
Myeloid-derived suppressor cells in cancer and cancer therapy
8天前
已完结
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
1个月前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
6个月前
已完结
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
6个月前
已完结
Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A phase II multi-center trial
6个月前
已完结
A pooled analysis of datopotamab deruxtecan in patients with EGFR–mutated NSCLC
6个月前
已完结
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
6个月前
已完结
Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study
6个月前
已完结
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)
6个月前
已完结
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
6个月前
已完结
皖公网安备34019202002308
